New Directions in RAS-Targeted Therapy: From Active-Conformation Inhibition to Protein Degradation
RAS mutations drive many tumors, including pancreatic cancer, colorectal cancer, and lung cancer. However, RAS was long considered difficult to drug because of its shallow structural pockets and tight GTP binding. The emergence of RAS(ON) inhibitors, molecular glues, and PROTACs has shifted RAS ...
危险品化学品经营许可证（带存储）